Most Common Side Effects of Artesunate
Artesunate, an antimalarial drug used for severe malaria, most frequently causes mild to moderate side effects like dizziness, nausea, vomiting, and fatigue. These occur in 10-20% of patients in clinical trials, resolving without intervention.[1]
How Often Do These Occur?
In intravenous use for severe malaria:
- Dizziness or vertigo: up to 19%
- Nausea: 12-15%
- Vomiting: 10-12%
- Anemia or low hemoglobin: 8-10%
- Injection site pain or rash: 5-8%
Oral forms report similar rates, with headache (around 15%) added. Frequencies vary by dose, duration (typically 3-7 days), and patient age—children experience less nausea but more parasite clearance-related effects.[2][1]
Serious but Less Frequent Risks
Rarely (under 1-2%), artesunate links to:
- Delayed hemolysis (4-6 weeks post-treatment), destroying red blood cells
- Hypersensitivity reactions like urticaria or anaphylaxis
- Liver enzyme elevations or hypoglycemia
Monitor hemoglobin for 4 weeks after IV use, especially in high-burden malaria areas.[3]
Side Effects in Children vs. Adults
Children under 15 (common recipients) see higher rates of fever reduction but similar GI issues; adults report more fatigue. Pregnancy data shows no fetal harm in second/third trimesters, but first-trimester use lacks full safety info.[2]
Compared to Other Antimalarials
Artesunate has a better tolerability profile than quinine (less tinnitus, hypoglycemia) but more post-treatment hemolysis than artemether-lumefantrine combinations. WHO recommends it over quinine for severe cases due to faster parasite clearance and fewer severe reactions.[1][3]
What Patients Report Most
User forums and post-marketing data highlight lingering fatigue and mild GI upset as top complaints, often lasting 1-2 weeks. Delayed anemia prompts follow-up questions from patients.[4]
[1]: WHO Guidelines for Malaria Treatment
[2]: CDC Artesunate Fact Sheet
[3]: NEJM Review on Artemisinin Safety
[4]: Drugs.com User Reviews